SS-31
SS-31 is a mitochondria-targeted tetrapeptide, developed clinically under the name elamipretide (also known as MTP-131 or Bendavia), that binds cardiolipin on the inner mitochondrial membrane and has been studied for its effects on cellular bioenergetics. It has advanced into human clinical trials for conditions tied to mitochondrial dysfunction, including primary mitochondrial myopathy, heart failure with preserved ejection fraction, and certain ophthalmic disorders. Outside of these sponsor-run trials, the compound circulates as a research chemical and is not an approved drug for any indication. Its clinical development has produced a notably mixed record, which is important context for interpreting the enthusiasm sometimes seen in community discussion.
Side effects & risks
The most commonly documented adverse effects in elamipretide trials are injection-site reactions, including redness, swelling, itching, and irritation at the subcutaneous injection site, which were frequent enough to be a notable tolerability issue. Other reported effects in clinical studies include headache, gastrointestinal symptoms such as nausea, and general reactions at or around the administration site. Because much community-sourced material comes from unregulated research-chemical suppliers, there is an additional and serious concern about purity, sterility, correct identity, and contamination that is independent of the peptide's own effects. The long-term safety of SS-31 in humans has not been established, and effects during pregnancy, breastfeeding, or alongside other medications are not well characterized. Injectable use also carries the usual risks of infection, bruising, and improper sterile technique. Side effects and risks should be weighed carefully and taken seriously rather than dismissed. Anyone considering this compound should consult a qualified clinician before use, particularly with any existing cardiac, renal, or other medical condition.
Latest studies
Mitochondria-targeted MXene-based nanozymes promote mitophagy and inhibit mtDNA-triggered cGAS/STING inflammation in osteoarthritis.
Researchers built a mitochondria-targeted nanomaterial for osteoarthritis that incorporates the peptide MTP-131 (SS-31) as a targeting component, alongside a cartilage-inductive peptide. In a mouse joint-injury model, the combined material was associated with better cartilage and bone outcomes.
Engineered Mitochondria-Targeted Biomimetic Hybrid Nanovesicles Ameliorate Rheumatoid Arthritis via Regulating Macrophage Autophagy and cGAS-STING Signaling.
Researchers built nanoparticles decorated with the mitochondria-targeting peptide SS-31 to deliver an anti-inflammatory compound to joint macrophages in a rodent arthritis model, reporting reduced inflammation in cells and animals.
Microvascular dysfunction and neurovascular signalling impairment in diabetic silent myocardial ischemia.
Some people with diabetes develop dangerously reduced blood flow to the heart without feeling any chest pain, a condition called silent myocardial ischemia. This review pulls together the biology thought to explain it — damaged small blood vessels plus nerve changes that mute pain signals — and points to mitochondrial stress as a common thread. Among many possible future therapies it briefly lists SS-31, a mitochondria-targeted peptide, alongside several drug classes. No new experiments were performed and no peptide was actually tested.
Community discussion
Community-reported · not verified
These are synthesised observations from public forum discussions. They are community-reported, not clinically verified, and should not inform any health decision. The peptide does not cure, treat, or prevent any condition based on these reports.
“Biohacking Advanced Level 4: SS-31”
An educational-style community post in a Philippines biohacking subreddit presenting SS-31 (elamipretide), a mitochondria-targeted peptide, as an advanced biohacking topic for discussion.
“Looking for experiences with SS-31, MOTS-C, DSIP& Epitalon.”
A user solicits firsthand experiences with SS-31, MOTS-C, DSIP, and epitalon, a cluster commonly grouped under mitochondrial and longevity interests. Replies compare perceived energy and sleep effects, discuss cycling versus continuous use, and note that the human evidence for each is limited and largely early-stage.
“Stack advice Reta CJC Klow ss31 etc”
A user seeks advice on a stack combining retatrutide, CJC-1295, and SS-31 among others.
“Looking for experiences with SS-31, MOTS-C, DSIP& Epitalon.”
A user requests community experiences with SS-31, MOTS-C, DSIP, and Epitalon, seeking observations on their use.
“Looking for experiences with SS-31, MOTS-C , DSIP& Epitalon .”
A user asks the community to share experiences with SS-31, MOTS-C, DSIP, and Epitalon, seeking firsthand observations.
Reported protocols (with caveats)
SS-31 is sold and used strictly as a research chemical, and no protocol described here should be read as medical guidance. In the clinical trials of elamipretide, the drug was typically administered by subcutaneous injection at daily doses reported in the range of roughly 40 mg, with some studies using intravenous infusion. In community and research settings, reported use most often involves reconstituted lyophilized peptide given by subcutaneous injection, with self-reported daily doses varying widely and frequently cited around 5 to 25 mg. Reported cycle lengths and frequencies are inconsistent across sources and are not standardized. These figures reflect research use only and unverified community reports, not validated or recommended dosing. Anyone considering the compound should recognize that safe and effective human dosing outside a monitored trial has not been established.